



Administer at least 30 mins prior to treatment.




#### PHYSICIAN ORDER SET:

### VEDOLIZUMAB LOAD (schedule weeks 0, 2, 6)

CDH 208-229 - Approved - Page 1 of 4

| Patient:  | DOB:             |                  | Gender:     |                           |  |  |
|---|------------------|------------------|-------------|---------------------------|--|--|
| Patient Phone #:  | Height:          |                  | Weight:     |                           |  |  |
| Diagnosis:  | ICD-10 Code:     |                  |             |                           |  |  |
| Treatment Start Date:   |                  |                  |             |                           |  |  |
| Provider Facility Name:   | Provider Facilit | y Address:       |             |                           |  |  |
| Ordering Provider:  | Date             | :                |             |                           |  |  |
| Signature:  |                  |                  |             |                           |  |  |
| Complete, Sign, and fax this doxument to: CDH Central Scheduling at 413-582-2183  **Please include H&P/current medications list/allergies, and ensure that med authorizations have been obtained**  Pre-Medications |                  |                  |             |                           |  |  |
|   |                  | Interval         | Defer Until | Duration                  |  |  |
| <ul><li>acetaminophen (TYLENOL) tablet 325 mg</li></ul>   |                  | Every 2          |             | 3 treatments              |  |  |
| 325 mg, Oral, Once, Starting S, For 1 Doses   |                  | weeks            |             |                           |  |  |
| Administer at least 30 mins prior to treatment.   |                  |                  |             |                           |  |  |
| ☐ diphenhydrAMINE (BENADRYL) oral 25 mg   |                  | Every 2<br>weeks |             | 3 treatments              |  |  |
| 25 mg, Oral, Once, Starting S, For 1 Doses  |                  |                  |             |                           |  |  |
| HOLD IF: Giving IV. Administer at least 30 mins prior to treatment  | •                |                  |             |                           |  |  |
| ☐ diphenhydrAMINE (BENADRYL) injection 25 mg  |                  |                  |             |                           |  |  |
|   |                  | Every 2          |             | 3 treatments              |  |  |
| 25 mg, Intravenous, Once, Starting S, For 1 Doses   |                  | Every 2<br>weeks |             | 3 treatments              |  |  |
| 25 mg, Intravenous, Once, Starting S, For 1 Doses HOLD IF: Giving PO. Administer at least 30 mins prior to treatmer   | nt.              | •                |             | 3 treatments              |  |  |
| HOLD IF: Giving PO. Administer at least 30 mins prior to treatmer  hydrocortisone sodium succinate (PF) (Solu-COR)  |                  | weeks Every 2    |             | 3 treatments 3 treatments |  |  |
| HOLD IF: Giving PO. Administer at least 30 mins prior to treatmer  hydrocortisone sodium succinate (PF) (Solu-COR 50 mg   |                  | weeks            |             |                           |  |  |
| HOLD IF: Giving PO. Administer at least 30 mins prior to treatmer  hydrocortisone sodium succinate (PF) (Solu-COR)  |                  | weeks Every 2    |             |                           |  |  |
| HOLD IF: Giving PO. Administer at least 30 mins prior to treatmer  hydrocortisone sodium succinate (PF) (Solu-COR' 50 mg 50 mg, Intravenous, Once, Starting S, For 1 Doses  |                  | weeks Every 2    |             |                           |  |  |





#### PHYSICIAN ORDER SET:

## VEDOLIZUMAB LOAD (schedule weeks 0, 2, 6) CDH 208-229 — Approved - Page 2 of 4

| Pre-H     | ydrations   |                     |                      |                          |  |
|-----------|---|---------------------|----------------------|--------------------------|--|
|           | sodium chloride 0.9% bolus 999 mL   | Interval<br>Every 2 | Defer Until          | Duration<br>3 treatments |  |
|           | 999 mL, Intravenous, for 1 Hours, Continuous, Starting S, For 1 Doses   | weeks               |                      |                          |  |
| N/ a alta |   |                     |                      |                          |  |
| wear      | cations   |                     |                      |                          |  |
|           | wedstimmer (ENTVIIO) IVDD and and Is 200 mm   | Interval            | Defer Until          | Duration                 |  |
|           | vedolizumab (ENTYVIO) IVPB orderable 300 mg   | Every 2<br>weeks    |                      | 3 treatments             |  |
|           | 300 mg, Intravenous, for 30 Minutes, Once, Starting H, For 1 Doses  |                     |                      |                          |  |
|           | Infuse week 0 , Week 2, week 6 then every 8 weeks Infuse over 30 minutes followed reconstitution  | by 30 ml NS flus    | sh Administer within | 4 hours of               |  |
| Post-     | Hydrations  |                     |                      |                          |  |
|           |   | Interval            | Defer Until          | Duration                 |  |
|           | sodium chloride 0.9% bolus 30 mL  | Every 2<br>weeks    |                      | 3 treatments             |  |
|           | 30 mL, Intravenous, Continuous, Starting S, For 1 Doses   | WEEKS               |                      |                          |  |
|           | , , , , , , , , , , , , , , , , , , ,   |                     |                      |                          |  |
| Labs      |   |                     |                      |                          |  |
|           |   | Interval            | Defer Until          | Duration                 |  |
|           | CBC and differential  | Every 2             |                      | 3 treatments             |  |
|           | Weeks Routine, Once, Starting S For 1 Occurrences, If deemed necessary based upon the results of the automated differential, a manual differential may be performed |                     |                      |                          |  |
|           | C-reactive protein, high sensitivity  | Every 2             |                      | 3 treatments             |  |
|           | Routine, Once, Starting S For 1 Occurrences   | weeks               |                      |                          |  |
|           | Sedimentation rate (ESR)  | Every 2             |                      | 3 treatments             |  |
|           | Journal of Fate (ESIT)  | weeks               |                      | o troutments             |  |
|           | Routine, Once, Starting S For 1 Occurrences   |                     |                      |                          |  |
|           | Comprehensive metabolic panel   | Every 2             |                      | 3 treatments             |  |
|           | Parties Once Charties C Ford Occurrences consists of the fallening tests. No. 1/ C  | weeks               | Onestining C         | Na lairean Allareania    |  |
|           | Routine, Once, Starting S For 1 Occurrences, consists of the following tests: Na, K, C Alkaline Phosphatase, Total Bilirubin, Total Protein, ALT, and AST           | i, CO2, BUN, Gi     | ucose, Creatinine, C | aicium, Aibumin,         |  |
|           | Basic metabolic panel   | Every 2             |                      | 3 treatments             |  |
|           | Positive Over Obertier O Ford Overroom. The best contabelling and best interest.  | weeks               | - N- 1/ 01 000 //-   | See als V. DUINI         |  |
|           | Routine, Once, Starting S For 1 Occurrences, The basic metabolic panel consists of the Glucose, Creatinine, and Calcium.  | ne following test   | s: Na, K, Cl, CO2 (b | icarb), BUN,             |  |
|           | LFTs (hepatic panel)  | Every 2             |                      | 3 treatments             |  |
|           |   | weeks               |                      |                          |  |
|           | Routine, Once, Starting S For 1 Occurrences, The hepatic panel consists of the follow Direct Bilirubin, Total Protein, ALT, and AST                                 | ring tests: Album   | nin, Alkaline Phosph | atase, Total and         |  |
|           | 25-OH vitamin D   | Every 2<br>weeks    |                      | 3 treatments             |  |
|           | Routine, Once, Starting S For 1 Occurrences   | 110010              |                      |                          |  |
|           | VITAMIN B12   | Every 2             |                      | 3 treatments             |  |
|           | Routine, Once, Starting S For 1 Occurrences   | weeks               |                      |                          |  |
|           |   |                     |                      |                          |  |


|     | (D ~.+ |     | CLI |      |
|-----|--------|-----|-----|------|
| - ( | 'Pati  | eni | SUL | .ker |



#### PHYSICIAN ORDER SET:

## VEDOLIZUMAB LOAD (schedule weeks 0, 2, 6) CDH 208-229 — Approved - Page 3 of 4

| La       | IDS (             | continued)   |                            |                        |                          |  |  |
|----------|-------------------|--|----------------------------|------------------------|--------------------------|--|--|
|          |                   |  | Interval                   | Defer Until            | Duration                 |  |  |
|          |                   | Ferritin   | Every 2                    |                        | 3 treatments             |  |  |
|          |                   | Destina Constitution Constitution Constitution   | weeks                      |                        |                          |  |  |
|          | _                 | Routine, Once, Starting S For 1 Occurrences  |                            |                        |                          |  |  |
|          | Ш                 | Iron and iron binding capacity   | Every 2<br>weeks           |                        | 3 treatments             |  |  |
|          |                   | Routine, Once, Starting S For 1 Occurrences, Plasma iron and TIBC are alway  |                            | Fransferrin saturation | n is calculated by       |  |  |
|          |                   | dividing the iron by the TIBC (Fe/TIBC).   | , ,                        |                        | ,                        |  |  |
|          | _                 | Inna   | F                          |                        | 2 tractice ante          |  |  |
|          | Ш                 | Iron   | Every 2<br>weeks           |                        | 3 treatments             |  |  |
|          |                   | Routine, Once, Starting S For 1 Occurrences  | WEEKS                      |                        |                          |  |  |
|          | $\Box$            | T spot TB test   | Every 2                    |                        | 3 treatments             |  |  |
|          |                   | ·  | weeks                      |                        |                          |  |  |
|          |                   | Routine, Once, Starting S For 1 Occurrences  |                            |                        |                          |  |  |
| <u></u>  | tho               | tor management   |                            |                        |                          |  |  |
| <u> </u> | attie             | ter management   | Intonial                   | Defer Until            | Duration                 |  |  |
|          |                   | Line Access  | Interval<br>PRN            | Defer Until            | Duration Until discont'd |  |  |
|          | Ш                 | Routine, Once, Starting S For 1 Occurrences, As needed. Starting when releas   |                            |                        | Offili discort d         |  |  |
|          |                   | Insert peripheral IV, or access peripheral, or central venous access device, to provide treatment.   |                            |                        |                          |  |  |
|          | $\overline{\Box}$ | alteplase (CATHFLO) 1 mg/mL injection 2 mg   | PRN                        |                        | Until discont'd          |  |  |
|          |                   | 2 mg, Intracatheter, As needed, line care, For central venous access device requiring clearance. Administer per institutional guidelines. May repeat once per lumen., Starting S                                 |                            |                        |                          |  |  |
|          |                   | lidocaine-prilocaine (EMLA) cream  | PRN                        |                        | Until discont'd          |  |  |
|          |                   | Topical, As needed, pre procedure/treatment, Apply prior to the PIV insertion o  | or port access, Starting S | 3                      |                          |  |  |
|          |                   | heparin 100 units/mL flush 5 mL  | PRN                        |                        | Until discont'd          |  |  |
|          |                   | 5 mL, Intravenous, As needed, line care, Line care per institutional guidelines,   | Starting S                 |                        |                          |  |  |
|          |                   | heparin 10 units/mL flush 3 mL   | PRN                        |                        | Until discont'd          |  |  |
|          |                   | 3 mL, Intravenous, As needed, line care, Line care per institutional guidelines,   | Starting S                 |                        |                          |  |  |
|          |                   | heparin 10 units/mL flush 5 mL   | PRN                        |                        | Until discont'd          |  |  |
|          |                   | 5 mL, Intravenous, As needed, line care, Line care per institutional guidelines,   | Starting S                 |                        |                          |  |  |
|          |                   | heparin 1000 units/mL flush 2 mL   | PRN                        |                        | Until discont'd          |  |  |
|          |                   | 2 mL, Intracatheter, As needed, line care, APHERESIS LINE CARE ONLY per institutional policy. HEPARIN MUST BE WITHDRAWN FROM EACH LUMEN PRIOR TO FLUSHING OR INFUSING THROUGH THE APHERESIS CATHETER, Starting S |                            |                        |                          |  |  |
|          |                   | sodium chloride (NS) 0.9 % syringe flush 3 mL  | PRN                        |                        | Until discont'd          |  |  |
|          |                   | 3 mL, Intravenous, As needed, line care, Line care per institutional guidelines,   | Starting S                 |                        |                          |  |  |
|          |                   | sodium chloride (NS) 0.9 % syringe flush 10 mL   | PRN                        |                        | Until discont'd          |  |  |
|          |                   | 10 mL, Intravenous, As needed, line care, Line care per institutional guidelines   |                            |                        |                          |  |  |
|          |                   | sodium chloride (NS) 0.9 % syringe flush 20 mL   | PRN                        |                        | Until discont'd          |  |  |
|          |                   | 20 mL, Intravenous, As needed, line care, Line care per institutional guidelines   |                            |                        |                          |  |  |
|          |                   | sodium chloride 0.9% infusion  | PRN                        |                        | Until discont'd          |  |  |
|          |                   | 20 mL/hr, Intravenous, Continuous PRN, other (free text field), Keep vein open   | ·                          | tarting S              |                          |  |  |
|          |                   | D5W infusion   | PRN                        | 1 - of the or O        | Until discont'd          |  |  |
|          |                   | 20 mL/hr, Intravenous, Continuous PRN, other (free text field), Keep vein open   | i to provide treatment, S  | tarting S              |                          |  |  |





#### PHYSICIAN ORDER SET:

# VEDOLIZUMAB LOAD (schedule weeks 0, 2, 6) CDH 208-229 — Approved - Page 4 of 4

| En   | nerg   | ency Medications  |                       |                         | _               |
|--|--|---|-----------------------|-------------------------|-----------------|
|  |  |   | Interval              | Defer Until             | Duration        |
|  |  | Provider and Nurse Communication  | PRN                   |                         | Until discont'd |
|  |  | Routine, Until discontinued, Starting S, Treatment of SEVERE reaction (ANAPHYLAXIS): hypotension, throat swelling, wheezing, respiratory distress, or decreased oxygen saturation. Stop the infusion and treat with epinephrine FIRST. Notify provider and emergency personnel, administer oxygen as needed, monitor vital signs and proceed with administering adjunct HYPERSENSITIVITY medications as clinically indicated. |                       |                         |                 |
|  |  | EPINEPHrine injection 0.3 mg  | PRN                   |                         | Until discont'd |
|  |  | 0.3 mg, Intramuscular, As needed, anaphylaxis, Administer FIRST for anaphylaxis   | s. May repeat times   | 1 dose, Starting S      |                 |
|  | For 2 doses. Pharmacy's Suggested Dose Instructions; Epinephrine 1:1000 is equivalent to 1 mg/mL |   |                       |                         |                 |
|  |  | sodium chloride 0.9% bolus 1,000 mL   | PRN                   |                         | Until discont'd |
|  |  | 1,000 mL, Intravenous, Once as needed, other (free text field), For hypotension, S  | Starting S, For 1 Dos | ses                     |                 |
|  |  | Oxygen Therapy - Non-Rebreather Routine   | PRN                   |                         | Until discont'd |
|  |  | Select a Mode of Therapy: Non-Rebreather  |                       |                         |                 |
|  | П  | Tryptase  | PRN                   |                         | Until discont'd |
|  |  | STAT, Once, Starting S For 1 Occurrences  |                       |                         |                 |
|  |  | Collect for mild-moderate, or SEVERE reaction   |                       |                         |                 |
|  |  |   |                       |                         |                 |
| Hy   | per  | sensitivity   |                       |                         |                 |
|  |  |   | Interval              | Defer Until             | Duration        |
|  |  | Provider and Nurse Communication  | PRN                   |                         | Until discont'd |
| Routine, Until discontinued, Starting S For Until specified, Treatment for mild-moderate infusion reaction: Stop the infusion, notify pro and emergency personnel, administer oxygen as needed, monitor vital signs and proceed with administering medications as clinically indicated. If ANAPHYLAXIS reaction, refer to Emergency Medications section. |  |   |                       |                         |                 |
|  |  | albuterol (ACCUNEB) nebulizer solution 2.5 mg   | PRN                   |                         | Until discont'd |
|  |  | 2.5 mg, Nebulization, Once as needed, shortness of breath, wheezing, wheezing,  | shortness of breath   | , Starting S, For 1 Do  | oses            |
|  |  | acetaminophen (TYLENOL) tablet 975 mg   | PRN                   |                         | Until discont'd |
|  |  | 975 mg, Oral, Once as needed, fever, Starting S, For 1 Doses  |                       |                         |                 |
|  |  | diphenhydrAMINE (BENADRYL) injection 25 mg  | PRN                   |                         | Until discont'd |
|  |  | 25 mg, Intravenous, As needed, itching, itching, hives. Begin with 25 mg. If patien   | t has continued read  | ction, administer addi  | tional 25 mg,   |
|  | _  | Starting S  | DDM                   |                         | 11.01.05        |
|  | Ш  | famotidine (PEPCID) injection 20 mg   | PRN                   |                         | Until discont'd |
|  |  | 20 mg, Intravenous, Once as needed, other (free text field), Adjunct treatment for premed, Starting S, For 1 Doses  | mild-moderate, or S   | EVERE reaction Hol      | d ir: given as  |
|  | П  | cetirizine (ZyrTEC) tablet 10-20 mg   | PRN                   |                         | Until discont'd |
|  |  | 10-20 mg, Oral, Once as needed, allergies, Adjunct treatment for mild-moderate, or  | or SEVERE reaction    | n, Starting S, For 1 D  | oses            |
|  |  | HOLD IF giving fexofenadine.  |                       |                         |                 |
|  |  | fexofenadine (ALLEGRA) tablet 90-180 mg   | PRN                   |                         | Until discont'd |
|  |  | 90-180 mg, Oral, Once as needed, allergies, Adjunct treatment for mild-moderate,  | , or SEVERE reaction  | on, Starting S, For 1 I |                 |
|  |  | HOLD IF giving cetirizine.  |                       |                         |                 |
|  |  | methylprednisolone sodium succinate (SOLU-Medrol) IV 40 m   | g PRN                 |                         | Until discont'd |
|  |  | 40 mg, Intravenous, Once as needed, other (free text field), Adjunct treatment for Doses  | -                     | EVERE reaction, Sta     | arting S, For 1 |
|  |  | ondansetron (ZOFRAN) injection 4 mg   | PRN                   |                         | Until discont'd |
|  |  | 4 mg Intravenous As needed nausea vomiting may repeat v 1 dose Starting S   | For 2 Docac           |                         |                 |